Venous and arterial disease in inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 7, 2013, Pages 1095-1113

  Tan, Victoria P ^a   Chung, Alvin ^c   Yan, Bryan P ^b   Gibson, Peter R ^d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MONASH UNIVERSITY   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Arteriosclerosis; Atherosclerosis; Deep venous thrombosis; Prevention; Pulmonary embolus; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CD40 ANTIGEN; CD40 LIGAND; FIBRINOLYTIC AGENT; HEPARIN; HEPARIN DERIVATIVE; HOMOCYSTEINE; WARFARIN;

ARTERIAL THROMBOEMBOLISM; ARTERIOSCLEROSIS; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMPRESSION GARMENT; EMBOLISM PREVENTION; ENTERITIS; FIBRINOLYTIC THERAPY; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS PREVENTION; VEIN DISEASE; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 84879425761     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12260     Document Type: Review

References (159)

1. Koutroubakis IE, Sfiridaki A, Tsiolakidou G etal. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm. Bowel Dis. 2007; 13: 410-415.
2. Miehsler W, Reinisch W, Valic E etal. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548.
3. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand. J. Gastroenterol. 2000; 35: 619-623.
4. Levy PJ, Tabares AH, Olin JW. Lower extremity arterial occlusions in young patients with Crohn's colitis and premature atherosclerosis: report of six cases. Am. J. Gastroenterol. 1997; 92: 494-497.
5. Koutroubakis IE. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis 2000; 18: 161-167.
6. Graef V, Baggenstoss AH, Sauer WG, Spittell JA. Venous thrombosis occurring in non specific ulcerative colitis. Ann. Intern. Med. 1966; 117: 377-382.
7. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 2001; 96: 1116-1122.
8. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm. Bowel Dis. 2011; 17: 471-478. 1002.
9. Bargen J, Barker N. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch. Intern. Med. 1936; 58: 17-31.
10. Srirajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2005; 17: 697-700.
11. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am. J. Gastroenterol. 2009; 104: 1445-1451.
12. Levine JB, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol. Clin. North Am. 1995; 24: 633-646.
13. Umit H, Asil T, Celik Y etal. Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report. World J. Gastroenterol. 2005; 11: 5404-5407.
14. Tsujikawa T, Urabe M, Bamba H etal. Haemorrhagic cerebral sinus thrombosis associated with ulcerative colitis: a case report of successful treatment by anticoagulant therapy. J. Gastroenterol. Hepatol. 2000; 15: 688-692.
15. Koutroubakis IE. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005; 2: 266-272.
16. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 2001; 85: 430-434.
17. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch. Intern. Med. 2007; 167: 935-943.
18. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 2008; 103: 2272-2280.
19. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663.
20. Novacek G, Weltermann A, Sobala A etal. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787, 87 e1.
21. Scarpa M, Pilon F, Pengo V etal. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J. Surg. 2010; 34: 1629-1636.
22. Kappelman MD, Horvath-Puho E, Sandler RS etal. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-943.
23. Saleh T, Matta F, Yaekoub AY, Danescu S, Stein PD. Risk of venous thromboembolism with inflammatory bowel disease. Clin. Appl. Thromb. Hemost 2011; 17: 254-258.
24. Sridhar AR, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J. Crohns Colitis 2011; 5: 287-294.
25. Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch. Surg. 2012; 147: 120-124.
26. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am. J. Gastroenterol. 2011; 106: 713-718.
27. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am. J. Gastroenterol. 2004; 99: 97-101.
28. Novacek G, Haumer M, Schima W etal. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm. Bowel Dis. 2004; 10: 430-435.
29. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007; 133: 1779-1786.
30. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am. J. Gastroenterol. 2008; 103: 2789-2798.
31. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment. Pharmacol. Ther. 2007; 25: 861-870.
32. Nuutinen H, Reunanen M, Farrkkila M. Association of ulcerative colitis and ischaemic heart disease. [Abstract]. Gastroenterology 1995; 110A: 886.
33. Nuutinen H, Reunanen M, Farrkkila M. Association of Crohn's disease and ischaemic heart disease. Gastroenterology 1996; 110A: 886.
34. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin. Proc. 1986; 61: 140-145.
35. Calderon R, Cruz-Correa MR, Torres EA. Cerebral thrombosis associated with active Crohn's disease. P. R. Health Sci. J. 1998; 17: 293-295.
36. Joshi D, Dickel T, Aga R, Smith-Laing G. Stroke in inflammatory bowel disease: a report of two cases and review of the literature. Thromb. J. 2008; 6: 2.
37. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann. Neurol. 1979; 5: 331-337.
38. Barclay AR, Keightley JM, Horrocks I, Garrick V, McGrogan P, Russell RK. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2010; 16: 677-683.
39. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 2008; 6: 41-45.
40. Efremidis M, Prappa E, Kardaras F. Acute myocardial infarction in a young patient during an exacerbation of ulcerative colitis. Int. J. Cardiol. 1999; 70: 211-212.
41. Mutlu B, Ermeydan CM, Enc F etal. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int. J. Cardiol. 2002; 83: 183-185.
42. Irving PM, Alstead EM, Greaves RR, Feakins RM, Pollok RC, Rampton DS. Acute mesenteric infarction: an important cause of abdominal pain in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 2005; 17: 1429-1432.
43. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am. J. Gastroenterol. 2007; 102: 174-186.
44. Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am. J. Gastroenterol. 2007; 102: 338-343.
45. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90: 183-188.
46. Koutroubakis IE, Malliaraki N, Vardas E etal. Increased levels of lipoprotein in Crohn's disease: a relation to thrombosis? Eur. J. Gastroenterol. Hepatol. 2001; 13: 1415-1419.
47. Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J. Atheroscler. Thromb. 2011; 18: 351-358.
48. Andersohn F, Waring M, Garbe E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm. Bowel Dis. 2010; 16: 1387-1392.
49. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am. J. Gastroenterol. 2011; 106: 741-747.
50. Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J. Crohns Colitis 2011; 5: 41-47.
51. Huerta C, Rivero E, Montoro MA, Garcia-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment. Pharmacol. Ther. 2011; 33: 969-978.
52. Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013; 62: 689-694.
53. Inamdar S, Altafi S, Sultan S. Increased risk of coronary artery disease among patients with inflammatory bowel disease. Gastroenterology 2012; 142 (Suppl. 1): 792-793.
54. Osterman MT, Yang YX, Brensinger CM, Lichenstein G, Lewis JD. Risk of myocardial infarction in ulcerative colitis and Crohn's disease. Clin. Gastroenterol. Hepatol. 2011; 9: 875-880.
55. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am. J. Gastroenterol. 2007; 102: 662-667.
56. van Langenberg DR, Simon SB, Holtmann GJ, Andrews JM. The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. J. Crohns Colitis 2010; 4: 413-421.
57. Sappati Biyyani RS, Fahmy NM, Baum E, Nelson KM, King JF. Inflammatory bowel disease and coronary artery disease. Indian J. Gastroenterol. 2009; 28: 28-30.
58. Guerin A, Pannier B, London G. Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol. 2007; 44: 187-198.
59. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984; 25: 653-659.
60. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010; 10: 826-837.
61. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ. J. 2010; 74: 213-220.
62. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat. Rev. Cardiol. 2010; 7: 528-536.
63. Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 2010; 55: 579-592.
64. Serrano CV Jr, Oranges M, Brunaldi V etal. Skeletonized coronary arteries: pathophysiological and clinical aspects of vascular calcification. Vasc. Health Risk Manag. 2011; 7: 143-151.
65. Pastore S, Londero M, Gortani G etal. Infliximab-related vasculitis in patients affected by ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 2010; 51: 226-228.
66. Bilgir O, Kebapcilar L, Bilgir F etal. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern. Med. 2010; 49: 1281-1285.
67. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr. Opin. Nephrol. Hypertens. 2005; 14: 525-531.
68. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002; 46: 862-873.
69. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Sharman JE, Coombes JS. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J. Atheroscler. Thromb. 2009; 17: 235-241.
70. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am. J. Kidney Dis. 2007; 49: 776-785.
71. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 1571-1575.
72. Maki-Petaja KM, Booth AD, Hall FC etal. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 2007; 50: 852-858.
73. Mukherjee S, Mukhopadhyay P, Pandit K, Chowdhury S. Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. J. Indian Med. Assoc. 2008; 106: 716-719.
74. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr. Vasc. Pharmacol. 2010; 8: 638-644.
75. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm. Bowel Dis. 2005; 11: 304-313.
76. Kirsner J, Shorter R. Inflammatory Bowel Disease. Baltimore, MD: Williams & Wilkins, 1995.
77. Wakefield AJ, Sawyerr AM, Dhillon AP etal. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-1062.
78. Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am. J. Physiol. Heart Circ. Physiol. 2003; 285: H1791-1796.
79. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125: 58-69.
80. Danese S, Sans M, Scaldaferri F etal. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J. Immunol. 2006; 176: 2617-2624.
81. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25: 1055-1059.
82. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109 (23 Suppl. 1): III27-32.
83. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004; 109 (23 Suppl. 1): III15-19.
84. Ganne F, Vasse M, Beaudeux JL etal. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins-consequences for plasmin generation and monocyte adhesion. Thromb. Haemost. 1999; 81: 594-600.
85. Ganne F, Vasse M, Beaudeux JL etal. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes-a possible protective mechanism against atherothrombosis. Thromb. Haemost. 2000; 84: 680-688.
86. Nissen SE, Tuzcu EM, Schoenhagen P etal. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080.
87. Nissen SE, Nicholls SJ, Sipahi I etal. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.
88. Ridker PM, Danielson E, Fonseca FA etal. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
89. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997; 336: 973-979.
90. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000; 342: 836-843.
91. Aikawa M, Sugiyama S, Hill CC etal. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002; 106: 1390-1396.
92. Aikawa M, Rabkin E, Okada Y etal. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433-2444.
93. Aikawa M, Voglic SJ, Sugiyama S etal. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999; 100: 1215-1222.
94. Bustos C, Hernandez-Presa MA, Ortego M etal. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 1998; 32: 2057-2064.
95. Beckman JA, Liao JK, Hurley S etal. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ. Res. 2004; 95: 217-223.
96. Tsunekawa T, Hayashi T, Kano H etal. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-379.
97. Kastelein JJ, Akdim F, Stroes ES etal. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 2008; 358: 1431-1443.
98. Levy E, Rizwan Y, Thibault L etal. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am. J. Clin. Nutr. 2000; 71: 807-815.
99. Ripolles Piquer B, Nazih H, Bourreille A etal. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 2006; 55: 980-988.
100. Romanato G, Scarpa M, Ruffolo C etal. Lipid and phospholipid profile after bowel resection for Crohn's disease. Int. J. Colorectal Dis. 2008; 23: 931-938.
101. Romanato G, Scarpa M, Angriman I etal. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2009; 29: 298-307.
102. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J. Clin. Lipidol. 2010; 4: 478-482.
103. McCully KS. Homocysteine and vascular disease. Nat. Med. 1996; 2: 386-389.
104. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-1168.
105. Oussalah A, Gueant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2011; 34: 1173-1184.
106. Stargrove MB, Treasure J, McKee DL. Herb, Nutrient and Drug Interactions: Clinical Implications and Therapeutic Strategies. St. Louis, MO: Mosby, 2008.
107. Mahmud N, Molloy A, McPartlin J etal. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999; 45: 389-394.
108. Williams HR, Willsmore JD, Cox IJ etal. Serum metabolic profiling in inflammatory bowel disease. Dig. Dis. Sci. 2012; 57: 2157-2165.
109. Bjerrum JT, Nielsen OH, Hao F etal. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J. Proteome Res. 2010; 9: 954-962.
110. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig. Dis. Sci. 2005; 50: 235-240.
111. Danese S, Sgambato A, Papa A etal. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am. J. Gastroenterol. 2005; 100: 886-895.
112. Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am. J. Gastroenterol. 2000; 95: 2825-2830.
113. Koutroubakis IE. Unraveling the mechanisms of thrombosis in inflammatory bowel disease. Am. J. Gastroenterol. 2001; 96: 1325-1327.
114. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993; 34: 247-251.
115. Chiarantini E, Valanzano R, Liotta AA etal. Hemostatic abnormalities in inflammatory bowel disease. Thromb. Res. 1996; 82: 137-146.
116. Danese S, Katz JA, Saibeni S etal. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52: 1435-1441.
117. Sawada-Hase N, Kiyohara T, Miyagawa J etal. An increased number of CD40-high monocytes in patients with Crohn's disease. Am. J. Gastroenterol. 2000; 95: 1516-1523.
118. Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 1997; 9: 1213-1217.
119. Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J. Gastroenterol. 2011; 17: 594-608.
120. Chamouard P, Grunebaum L, Wiesel ML etal. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 1995; 7: 1183-1188.
121. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am. J. Dig. Dis. 1978; 23: 897-902.
122. Souto JC, Martinez E, Roca M etal. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig. Dis. Sci. 1995; 40: 1883-1889.
123. Saibeni S, Vecchi M, Valsecchi C, Faioni EM, Razzari C, de Franchis R. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig. Dis. Sci. 2001; 46: 637-643.
124. Jorens PG, Hermans CR, Haber I, Kockx MM, Vermylen J, Parizel GA. Acquired protein C and S deficiency, inflammatory bowel disease and cerebral arterial thrombosis. Blut 1990; 61: 307-310.
125. Larsen TB, Nielsen JN, Fredholm L etal. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol. Haemost. Thromb. 2002; 32: 92-96.
126. Koutroubakis IE, Sfiridaki A, Mouzas IA etal. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 2000; 95: 190-194.
127. Faioni EM, Ferrero S, Fontana G etal. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit. Care Med. 2004; 32 (5 Suppl.): S266-270.
128. Gris JC, Schved JF, Raffanel C etal. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb. Haemost. 1990; 63: 472-475.
129. Saibeni S, Bottasso B, Spina L etal. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am. J. Gastroenterol. 2004; 99: 1966-1970.
130. Koschinsky ML. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr. Atheroscler. Rep. 2005; 7: 389-395.
131. Koutroubakis IE, Petinaki E, Anagnostopoulou E etal. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 1998; 43: 2507-2512.
132. Heneghan MA, Cleary B, Murray M, O'Gorman TA, McCarthy CF. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig. Dis. Sci. 1998; 43: 1356-1361.
133. Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am. J. Gastroenterol. 2005; 100: 2036-2041.
134. Hommes DW, van Dullemen HM, Levi M etal. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 1997; 27: 269-277.
135. van der WoUde CJ, Kolacek S, Dotan I etal. European evidenced-based consensus on reproduction in inflammatory bowel disease. J. Chrons Colitis 2010; 4: 493-510.
136. Wakefield AJ, Sankey EA, Dhillon AP etal. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100 (5 Pt 1): 1279-1287.
137. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2010; 105: 501-523; quiz 24.
138. Geerts WH, Bergqvist D, Pineo GF etal. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl.): 381S-453S.
139. Mowat C, Cole A, Windsor A etal. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
140. Travis SP, Stange EF, Lemann M etal. European evidence-based Consensus on the management of ulcerative colitis: current management. J. Crohns Colitis 2008; 2: 24-62.
141. Van Assche G, Dignass A, Reinisch W etal. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J. Crohns Colitis 2009; 4: 63-101.
142. Dignass A, Lindsay JO, Sturm A etal. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J. Crohns Colitis 2012; 6: 991-1030.
143. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am. J. Gastroenterol. 1995; 90: 220-223.
144. Kao A, Dlugos D, Hunter JV, Mamula P, Thorarensen O. Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children. J. Child Neurol. 2002; 17: 479-482.
145. Vrij AA, Jansen JM, Schoon EJ, de Bruine A, Hemker HC, Stockbrugger RW. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand. J. Gastroenterol. Suppl. 2001; 234: 41-47.
146. Ageno W, Squizzato A, Ambrosini F etal. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87: 746-750; discussion 250.
147. Cohen AT. Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thromb. Haemost. 2010; 104: 919-930.
148. Kaatz S, Spyropoulos AC. Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care. Hosp. Pract. (Minneap) 2011; 39: 7-15.
149. Aryal KR, Al-Khaffaf H. Venous thromboembolic complications following air travel: what's the quantitative risk? A literature review. Eur. J. Vasc. Endovasc. Surg. 2006; 31: 187-199.
150. Tinsley A, Naymagon S, Trindade AJ, Sachar DB, Sands BE, Ullman TA. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J. Clin. Gastroenterol. 2013 (Jan); 47 (1): e1-6.
151. Chung AR, Mahindra P, Garg M, Gibson PR. Failure to assess cardiovascular risk factors in patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 4): 60.
152. Chan SS, Luben R, Bergmann MM etal. Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment. Pharmacol. Ther. 2011; 34: 649-655.
153. Ananthakrishnan AN, Higuchi LM, Huang ES etal. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann. Intern. Med. 2012; 156: 350-359.
154. Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur. J. Clin. Pharmacol. 2009; 65: 963-970.
155. Lonn E, Yusuf S, Arnold MJ etal. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006; 354: 1567-1577.
156. Szychta P, Reix T, Sevestre MA, Brazier F, Pietri J. Aortic thrombosis and ulcerative colitis. Ann. Vasc. Surg. 2001; 15: 402-404.
157. Lengle SJ, Nadler P, Jordan GW. Arterial thrombosis in ulcerative colitis. Transcatheter thrombolytic therapy. West. J. Med. 1995; 162: 543-547.
158. Chande N, MacDonald JK, Wang JJ, McDonald JW. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm. Bowel Dis. 2011; 17: 1979-1986.
159. Thorsteinsson GS, Magnussson M, Hallberg LM etal. Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis. World J. Gastroenterol. 2008; 14: 4576-4579.